Biogen Receives EU Approval For Spinraza

Biogen Receives EU Approval For Spinraza

Biogen and Ionis Pharmaceuticals said Thursday that the European Commission has granted a marketing authorization for Spinraza in the treatment of 5q spinal muscular atrophy. Biogen was responsible for the commercialization of the drug and Ionis is eligible for milestone payments and royalties. Ionis said it has earned a $50 million milestone payment from Biogen in connection with the EU approval. Ionis is also eligible to receive tiered sales royalties […]

Read More ˃